Luisa M. Villar

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 197 publications

Interleukin-2 is associated with cytopenias in systemic lupus erythematosus.

Interleukin-2 is associated with cytopenias in systemic lupus erythematosus.

Journal: Autoimmunity

Published: July 25, 2026

Ultrasensitive serum interferon alpha equals interferon signatures as a marker of lupus disease activity.

Ultrasensitive serum interferon alpha equals interferon signatures as a marker of lupus disease activity.

Journal: iScience

Published: April 15, 2026

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

Journal: International journal of molecular sciences

Published: April 15, 2026

Discontinuation of disease-modifying therapies in patients with multiple sclerosis: A retrospective case-control study.

Discontinuation of disease-modifying therapies in patients with multiple sclerosis: A retrospective case-control study.

Journal: Multiple sclerosis and related disorders

Published: March 21, 2026

miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: February 13, 2026

Serum interleukin-2 levels associate with disease activity and cardiovascular risk in patients with rheumatoid arthritis.

Serum interleukin-2 levels associate with disease activity and cardiovascular risk in patients with rheumatoid arthritis.

Journal: Clinical and experimental rheumatology

Published: February 03, 2026

A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.

A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.

Journal: Frontiers in immunology

Published: February 02, 2026

Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesis.

Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesis.

Journal: Scientific reports

Published: January 12, 2026

Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesis.

Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesis.

Journal: Scientific reports

Published: January 12, 2026

Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.

Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.

Journal: Therapeutic advances in neurological disorders

Published: January 09, 2026

HERV-W association with serum biomarkers NfL and GFAP in multiple sclerosis.

HERV-W association with serum biomarkers NfL and GFAP in multiple sclerosis.

Journal: Frontiers in immunology

Published: December 26, 2025

The CD5-CK2-STAT3 axis in Th17 cell polarization: implications for multiple sclerosis.

The CD5-CK2-STAT3 axis in Th17 cell polarization: implications for multiple sclerosis.

Journal: Brain : a journal of neurology

Published: December 15, 2025

Showing 1-12 of 197

Last Updated: 09/26/2026